Canada Lets Four Terminally Ill Patients Use Psilocybin

Facebook ↗WhatsApp ↗

Originally published 2020-08-13.

Canada's 2020 Psilocybin Exemptions for Terminally Ill Patients

On 4 August 2020, Canada's health minister Patty Hajdu granted four people with incurable cancer a legal exemption to possess and use psilocybin, the active compound in "magic mushrooms", to ease the anxiety and despair that can come at the end of life. It was the first time anyone in Canada had been allowed to use psilocybin legally since the drug was banned in 1974. The decision did not legalise mushrooms, and it did not approve psilocybin as a medicine. It made an exception, on compassionate grounds, for four named patients.

Here is what the exemption actually allowed, how it came about, what the science says about psilocybin in palliative care, and what changed in the years afterwards.

What the exemption allowed, and what it did not

The legal tool was section 56(1) of Canada's Controlled Drugs and Substances Act. It lets the health minister exempt a person or a substance from the law when that is "necessary for a medical or scientific purpose or is otherwise in the public interest". Canada's first legal medical access to cannabis was also won through section 56, years before cannabis was legalised.

Psilocybin remained a controlled substance in Canada, and Health Canada noted at the time that there were no approved therapeutic products containing it. The four patients could use it under supervision as part of psilocybin-assisted psychotherapy. Nobody else gained any new rights, and selling or growing psilocybin mushrooms stayed illegal.

The decision came after a refusal. In 2017 a group of doctors had applied under section 56 to use psilocybin for patients in terminal distress, and in March 2020 that application was denied for "insufficient evidence to demonstrate the medical need". The August approvals therefore marked a real shift in how the ministry weighed individual patients' requests.

The patients and the campaign behind them

The four applicants applied in April 2020, supported by TheraPsil, a non-profit coalition of patients, doctors and therapists which campaigns for legal access to psilocybin therapy. Its founder, the psychotherapist Dr Bruce Tobin, welcomed the decision and said the government had shown a willingness to listen to "patients who have not been heard".

One of the four, Thomas Hartle, who was living with terminal cancer, spoke publicly about his relief, describing the approval as an act of real compassion by officials. Another, Laurie Brooks, said she hoped the decision was a first step and that other Canadians would one day be able to access the therapy without spending months petitioning the government.

Their point was a practical one. A person with a terminal diagnosis may not have months to wait for paperwork, and in 2020 each application had to be considered individually by the minister.

What psilocybin is and how it works

Psilocybin occurs naturally in more than 200 species of mushroom. In the body it is converted into psilocin, which acts on the brain's serotonin receptors, especially the 5-HT2A receptor that is responsible for its hallucinogenic effects. A typical experience lasts several hours and can bring altered perception, strong emotions and a changed sense of self.

The Swiss chemist Albert Hofmann, best known for discovering LSD, isolated psilocybin in 1958, and his employer Sandoz later supplied it to clinicians for research. That early research largely stopped after psychedelics were placed under strict international control by the 1971 UN Convention on Psychotropic Substances.

What research says about end-of-life distress

The modern revival of psilocybin research has focused heavily on the kind of suffering the Canadian patients described. In 2016, two randomised trials at Johns Hopkins University and New York University gave single, carefully supported doses of psilocybin to people with life-threatening cancer and reported large, lasting reductions in anxiety and depression in many participants. Those trials were small, and the treatment was always paired with preparation and talking therapy, not taken alone.

Since then the evidence base has grown. A 2023 systematic review and meta-analysis found substantial reductions in depressive symptoms with psilocybin therapy across major depression, treatment-resistant depression and depression linked to life-threatening cancer. In the United States, the FDA granted psilocybin "breakthrough therapy" status in 2018 and 2019 to speed up research into depression treatments. Brain-imaging studies suggest the drug temporarily loosens activity in the default mode network, a set of brain regions linked to rigid, self-focused thinking.

Researchers are careful to say that this is not a cure, and that results depend heavily on screening, setting and professional support.

Risks and common myths

Psilocybin has low physical toxicity and is not associated with physical dependence, but it is not harmless. Nausea, vomiting, poor coordination, frightening experiences and panic attacks are common reported effects, and psychotic-like episodes can occur, especially at high doses or in people with a personal or family history of psychosis. It is considered unsuitable during pregnancy and breastfeeding.

  • Myth: "Canada legalised magic mushrooms in 2020." It did not. Four individual exemptions were granted, and psilocybin remained illegal to sell, grow or possess without one.
  • Myth: "If it helps in trials, taking mushrooms at home is the same." Trial results come from measured doses, medical screening and trained therapists. Wild mushrooms vary widely in strength, and some poisonous species look similar.
  • Myth: "Psychedelic therapy works for everyone." Many participants improve, but some do not, and some have distressing experiences.

Anyone thinking about psilocybin for anxiety, depression or end-of-life distress should talk to a doctor first, ideally about legal clinical trials or approved access programmes.

What changed after 2020

The four exemptions turned out to be the start of a longer process. Health Canada went on to approve further exemptions, including for some health care professionals who wanted to experience psilocybin therapy themselves as part of their training. By 2023, more than 50 Canadians had received psilocybin-assisted therapy on compassionate grounds.

Elsewhere, Australia allowed authorised psychiatrists to prescribe psilocybin for treatment-resistant depression from 2023, one of the first countries to do so nationally. The research barrier described in 2020, that illegality made trials slow and expensive, has eased but not vanished: psilocybin is still tightly controlled almost everywhere.

For the four Canadians, the change was immediate and personal. For everyone else, their case showed that a narrow legal door could open when patients, doctors and evidence came together. You can read more on the science in our article on psilocybin research and the idea of resetting the brain.

Sources: MLT Aikins, August 2020: Magic moment, an exemption to the Controlled Drugs and Substances Act granted; Rolling Stone: Canada lets terminal patients use magic mushrooms; High Times: Canada allowing psilocybin access for terminally ill patients; Wikipedia: Psilocybin; Wikipedia: Psilocybin therapy.

COMMENTS